The Effect of Recombinant Human Erythropoietin on the Development of Retinopathy of Prematurity

 

 Buy Article Permissions and Reprints

ABSTRACT

In addition to its hematopoietic effects, erythropoietin causes an increased release of endothelin-1 and the stimulation of angiogenesis and thereby it may have possible role in development of retinopathy of prematurity (ROP). Our objective was to determine if an association exists between recombinant human erythropoietin (rhEPO) treatment and the development of ROP. Our case-control study involved 85 very low birthweight infants with birthweights <1500 g born during 2003 and 2004. All the infants were divided into two groups on the basis of whether they got rhEPO or not. The rhEPO was given at the dose of 200 to 250 units/kg/dose three times a week for 10 doses. Further duration of rhEPO therapy was decided on the basis of the clinical response. Ophthalmological examinations were done at the age of 5 to 6 weeks and were repeated 1 to 4 weeks after the first examination according to the severity of the ROP disease during their in-hospital stay. Of 85 infants, 56 (66%) received rhEPO and 29 (34%) did not. In the rhEPO-treated group, 12 infants (21%) had ROP; in the non-rhEPO group, 11 infants (38%) developed ROP. This difference is not statistically significant (odds ratio = 2.63; p = 0.10). There was no correlation between the use of rhEPO and the stage of ROP (random sample = −0.01; p = 0.89). There was no significant difference in the incidence of plus, prethreshold, or threshold disease and the treatment required for ROP between the rhEPO-treated and the nontreated group. The study showed there is no significant difference in the incidence and severity of ROP between the rhEPO-treated and nontreated group.

REFERENCES

• 1 Steinkuller P G, Du L, Gilbert C, Foster A, Collins M L, Coats D K. Childhood blindness.  J AAPOS. 1999;  3(1) 26-32
  PubMedGoogle Scholar
• 2 Ashton N, Ward B, Serpell G. Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia.  Br J Ophthalmol. 1954;  38(7) 397-432
  CrossrefPubMedGoogle Scholar
• 3 Smith L E, Shen W, Perruzzi C et al.. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor.  Nat Med. 1999;  5(12) 1390-1395
  Google Scholar
• 4 Morita M, Ohneda O, Yamashita T et al.. HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin.  EMBO J. 2003;  22(5) 1134-1146
  CrossrefPubMedGoogle Scholar
• 5 Donahue M L, Phelps D L, Watkins R H, LoMonaco M B, Horowitz S. Retinal vascular endothelial growth factor (VEGF) mRNA expression is altered in relation to neovascularization in oxygen induced retinopathy.  Curr Eye Res. 1996;  15(2) 175-184
  CrossrefPubMedGoogle Scholar
• 6 Stone J, Chan-Ling T, Pe'er J, Itin A, Gnessin H, Keshet E. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity.  Invest Ophthalmol Vis Sci. 1996;  37(2) 290-299
  PubMedGoogle Scholar
• 7 Adamis A P, Shima D T, Tolentino M J et al.. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate.  Arch Ophthalmol. 1996;  114(1) 66-71
  CrossrefPubMedGoogle Scholar
• 8 Goldberg M A, Schneider T J. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin.  J Biol Chem. 1994;  269(6) 4355-4359
  PubMedGoogle Scholar
• 9 Heeschen C, Aicher A, Lehmann R et al.. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization.  Blood. 2003;  102(4) 1340-1346
  CrossrefPubMedGoogle Scholar
• 10 Carlini R G, Reyes A A, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro.  Kidney Int. 1995;  47(3) 740-745
  CrossrefPubMedGoogle Scholar
• 11 Ohlsson A, Aher S M. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants.  Cochrane Database Syst Rev. 2006;  (3) CD004863
  PubMedGoogle Scholar
• 12 Calhoun D A, Christensen R D, Edstrom C S et al.. Consistent approaches to procedures and practices in neonatal hematology.  Clin Perinatol. 2000;  27(3) 733-753
  PubMedGoogle Scholar
• 13 The Committee for the Classification of Retinopathy of Prematurity . An international classification of retinopathy of prematurity.  Arch Ophthalmol. 1984;  102(8) 1130-1134
  CrossrefPubMedGoogle Scholar
• 14 Maier R F, Obladen M, Kattner E et al.. High-versus low-dose erythropoietin in extremely low birth weight infants. The European Multicenter rhEPO Study Group.  J Pediatr. 1998;  132(5) 866-870
  PubMedGoogle Scholar
• 15 Ohls R K, Harcum J, Schibler K R, Christensen R D. The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double-blind, placebo-controlled study.  J Pediatr. 1997;  131(5) 661-665
  PubMedGoogle Scholar
• 16 Carlini R G, Dusso A S, Obialo C I, Alvarez U M, Rothstein M. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells.  Kidney Int. 1993;  43(5) 1010-1014
  CrossrefPubMedGoogle Scholar
• 17 Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity.  Nat Med. 1995;  1(10) 1024-1028
  CrossrefPubMedGoogle Scholar
• 18 Türker G, Sarper N, Gökalp A S, Usluer H. The effect of early recombinant erythropoietin and enteral iron supplementation on blood transfusion in preterm infants.  Am J Perinatol. 2005;  22(8) 449-455
  Article in Thieme ConnectPubMedGoogle Scholar
• 19 Brown M S, Barón A E, France E K, Hamman R F. Association between higher cumulative doses of recombinant erythropoietin and risk for retinopathy of prematurity.  J AAPOS. 2006;  10(2) 143-149
  CrossrefPubMedGoogle Scholar
• 20 Romagnoli C, Zecca E, Gallini F, Girlando P, Zuppa A A. Do recombinant human erythropoietin and iron supplementation increase the risk of retinopathy of prematurity?.  Eur J Pediatr. 2000;  159(8) 627-628
  CrossrefPubMedGoogle Scholar
• 21 Ohls R K, Ehrenkranz R A, Wright L L et al.. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial.  Pediatrics. 2001;  108(4) 934-942
  CrossrefPubMedGoogle Scholar
• 22 Donato H, Vain N, Rendo P et al.. Effect of early versus late administration of human recombinant erythropoietin on transfusion requirements in premature infants: results of a randomized, placebo-controlled, multicenter trial.  Pediatrics. 2000;  105(5) 1066-1072
  CrossrefPubMedGoogle Scholar
• 23 Williamson P, Griffiths G, Norfolk D, Levene M. Blood transfusions and human recombinant erythropoietin in premature newborn infants.  Arch Dis Child Fetal Neonatal Ed. 1996;  75(1) F65-F68
  CrossrefPubMedGoogle Scholar
• 24 Hardy R J, Palmer E A, Schaffer D B, Phelps D L, Davis B R, Cooper C J. Outcome-based management of retinopathy of prematurity. Multicenter Trial of Cryotherapy for Retinopathy of prematurity Cooperative Group.  J AAPOS. 1997;  1(1) 46-54
  PubMedGoogle Scholar

M. Roger KimM.D. 

Division of Neonatology, Department of Pediatrics

Brookdale University Hospital and Medical Center, Brookdale Plaza, Brooklyn, NY 11212

Email: RKim@Brookdale.edu